| Allogene Therapeutics Inc (ALLO) | |||
|---|---|---|---|
| 2.89 0.035 (1.23%) | 04-26 16:00 | ||
| Open: | 2.87 | Pre. Close: | 2.855 |
| High: | 2.93 | Low: | 2.75 |
| Volume: | 2,424,911 | Market Cap: | 493(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 4.57  One year: 5.41 |
| Support: | Support1: 2.75 Support2: 2.29 |
| Resistance: | Resistance1: 3.91 Resistance2: 4.63 |
| Pivot: | 3.53 |
| Moving Averages: | MA(5): 3.11 MA(20): 3.68 MA(100): 3.81  MA(250): 4.09 |
| MACD: | MACD(12,26): -0.36 Signal(12,26,9): -0.29 |
| %K %D: | %K(14,3): 3.73 %D(3): 2.01 |
| RSI: | RSI(14): 21.58 |
| 52-Week: | High: 6.89 Low: 2.23 Change(%): -46.8 |
| Average Vol(K): | 3-Month: 2292 10-Days: 1936 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 2.937 - 2.956 | 2.956 - 2.974 |
| Low: | 2.704 - 2.728 | 2.728 - 2.749 |
| Close: | 2.852 - 2.891 | 2.891 - 2.926 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed above bottom band by 8.7%. Bollinger Bands are 39.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 169.09 |
| % Held by Insiders | 111000000.00 |
| % Held by Institutions | 22.44 |
| Shares Short (K) | 25010 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -300289984.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | 163.00 |
| Return on Assets (ttm) | 475.0 |
| Return on Equity (ttm) | -26.8 |
| Qtrly Rev. Growth | 95000.0 |
| Gross Profit (p.s.) | |
| Sales Per Share | -69.387 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -2.09 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -237.73 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | -2.10 |
| Price to Book value | |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.76 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 30620000.000 |
